Search Results - "Garbo, E."

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer by Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., Galimi, F., McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S.

“…We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death…”
Get full text

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer by Sonpavde, Guru, M.D, Aparicio, Ana M., M.D, Zhan, Feng, Ph.D, North, Brittany, B.Sc, DeLaune, Robert, M.D, Garbo, Lawrence E., M.D, Rousey, Steven R., M.D, Weinstein, Ralph E., M.D, Xiao, Lianchun, M.S, Boehm, Kristi A., M.S, Asmar, Lina, Ph.D, Fleming, Mark T., M.D, Galsky, Matthew D., M.D, Berry, William R., M.D, Von Hoff, Daniel D., M.D

“…Abstract Background Azacitidine is a hypomethylating agent that activates genes repressed by promoter methylation. Preclinically, demethylating agents reverse…”
Get full text

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma by Murray Stewart, Tracy, Von Hoff, Daniel, Fitzgerald, Michael, Marton, Laurence J., Becerra, Carlos H. Roberto, Boyd, Thomas E., Conkling, Paul R., Garbo, Lawrence E., Jotte, Robert M., Richards, Donald A., Smith, David A., Stephenson, Joe J., Vogelzang, Nicholas J., Wu, Hillary H., Casero, Robert A.

“…Purpose Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the…”
Get full text

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis by Reale, M.L., Capelletto, E., Buttigliero, C., Bordi, P., Ricciardi, S., Belluomini, L., Garbo, E., Leonetti, A., Lombardi, A., Dodi, A., Napoli, V., Casali, M., Soregaroli, D., Insolda, J., Bironzo, P., Tiseo, M., Migliorino, M.R., Pilotto, S., Passiglia, F., Novello, S.

Get full text

182P METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation by Becerra, M.V. Sanchez, Pecci, F., Aldea, M., Ricciuti, B., Garbo, E., Zrafi, W.S., Artahona, V.M. Albarran, Makarem, M., Saini, A., Paoloni, F., Lavaud, P., Frelaut, M., Abdayem, P., Parisi, C., Planchard, D., Barlesi, F., Awad, M., Besse, B., Masip, J. Remon

Get full text

203P Treatment patterns and real-world outcomes of extensive-stage small cell lung cancer: A retrospective, multicenter study by Cani, M., Buffoni, L., Bertaglia, V., Facilissimo, I., Allione, P., Paratore, C., Vavala, T., Borra, G., Pignataro, D., Granetto, C., Pietrogiovanna, L., Rizzo, F., Zullo, L., Garbo, E., Bironzo, P., Novello, S.

Get full text

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma by Garbo, Lawrence E., Flynn, Patrick J., MacRae, Margaret A., Rauch, Mary A., Wang, Yunfei, Kolibaba, Kathryn S.

“…Summary Background : Gemcitabine (G) has shown activity in mantle cell lymphoma (MCL) as a single agent. The combination of mitoxantrone (M) and rituximab (R)…”
Get full text

Vitamin E supplementation in preeclampsia by Stratta, P, Canavese, C, Porcu, M, Dogliani, M, Todros, T, Garbo, E, Belliardo, F, Maina, A, Marozio, L, Zonca, M

“…An oxidant/antioxidant imbalance has been suggested among the pathogenetic factors involved in preeclampsia. As vitamin E is one of the most important…”
Get more information

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA by Liu, M.C., Klein, E.A., Swanton, C., Seiden, M.V., Klein, Eric A., Yeatman, Timothy J., Cohn, Allen L., Lapham, Rosanna, Parker, Alexander S., McIntyre, Kristi, Sekeres, Mikkael A., Siegel, Robert, Wang, Xuezhong, Cosgrove, David P., Trent, Jonathan, Thiel, David D., Garbo, Lawrence E., Giguere, Jeffrey K., Michels, Ross M., Harris, Ronald P., Richey, Stephen L., McCarthy, Timothy A., Couch, Fergus J., Wilks, Sharon T., Krie, Amy K., Balaraman, Rama, Rieger-Christ, Kimberly, Sullivan, Travis, Greenwald, Daniel R., Oh, William, Tsao, Che-Kai, Kennecke, Hagen F., Manhas, Atisha P., Ulrich, Brian K., Kovoor, Philip A., Stokoe, Christopher, Courtright, Jay G., Larson, Timothy G., Seiden, Michael V., Cummings, Steven R., Absalan, Farnaz, Alexander, Gregory, Allen, Brian, Aravanis, Alexander M., Beausang, John F., Berman, Jennifer, Bredno, Joerg, Calef, Robert, Cann, Gordon, Carter, Jeremy, Chen, Xiaoji, Chien, Tom C., Davydov, Konstantin, Demas, Vasiliki, Fields, Alexander P., Freese, Peter, Gnerre, Sante, Gross, Samuel, Hall, Megan P., Hartman, Anne-Renee, Hou, Chenlu, Hubbell, Earl, Jiang, Roger, Kim, TaeHyung, Klausner, Richard D., Kurtzman, Kathryn N., Lee, Mark, Lin, Wendy, Lipson, Jafi, Maddala, Tara, Maher, M. Cyrus, Melton, Collin, Mich, Andrea, Newman, Joshua, Nicula, Virgil, Nikolic, Ongjen, Patel, Shilpen, Rava, Richard, Schellenberger, Jan, Scott, Eric, Sehnert, Amy J., Shaknovich, Rita, Shanmugam, Avinash, Shashidhar, K.C., Shenoy, Archana, Shojaee, Seyedmehdi, Tang, Susan, Valouev, Anton, Venn, Oliver, Williams, Richard T., Wu, Tony, Yakym, Christopher, Yang, Xiao, Yecies, Jessica, Yip, Alexander S., Yue, Jeanne, Zhang, Lily, Zhang, Lori (Quan), Curtis, Christina, Berry, Donald A.

“…Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from…”
Get full text

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC) by Fakih, Marwan, Raghav, Kanwal Pratap Singh, Chang, David Z., Bendell, Johanna C., Larson, Timothy, Cohn, Allen Lee, Huyck, Timothy K., Cosgrove, David, Fiorillo, Joseph A., Garbo, Lawrence E., Ravimohan, Shruthi, Potter, Von, D'Adamo, David, Sharma, Neelesh, Wang, Ying A., Coppieters, Sabine, Herpers, Matthias, Soares Viana de Oliveira, Carolina, Paulson, Andrew Scott

“…Abstract only 3560 Background: The role of immunotherapy in the treatment of pMMR/MSS metastatic CRC is not established. A Japanese phase 1b trial in this…”
Get full text

Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors by Albany, Costantine, Feldman, Darren Richard, Garbo, Lawrence E., Einhorn, Lawrence H.

“…Abstract only 327 Background: Brentuximab Vedotin (BV) is a novel antibody drug conjugate that combines the agent mono-methyl auristatin E (MMAE) to a CD-30…”
Get full text

A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study by Lyons, Roger M., Marek, Billie J., Paley, Carole S., Esposito, Jason, Garbo, Lawrence E., DiBella, Nicholas J., Garcia-Manero, Guillermo

“…Abstract only 7122 Background: Many patients (pts) with lower-risk myelodysplastic syndromes (MDS) require chronic red blood cell transfusions for symptomatic…”
Get full text

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma by Becerra, Carlos, Stephenson, Joe, Jonker, Derek J., Cohn, Allen Lee, Asmis, Timothy R., Bekaii-Saab, Tanios S., Conkling, Paul R., Garbo, Lawrence E., Lenz, Heinz-Josef, Richards, Donald A., Spira, Alexander I., Mikhail, Sameh, Goodwin, Rachel Anne, Yoon, Harry H., Hume, Stephanie, Hitron, Matthew, Li, Chiang

“…Abstract only…”
Get full text

SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy by Kim, Edward S., Neubauer, Marcus A., Cohn, Allen Lee, Schwartzberg, Lee Steven, Garbo, Lawrence E., Caton, John Robert, Robert, Francisco, Katz, Terry, Chittoor, Sreenivas, Simms, Lorinda, Saxman, Scott

“…Abstract only 7502 Background: SELECT investigated whether the addition of C to standard chemotherapy improved progression-free survival (PFS) in patients…”
Get full text

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors by Tabernero, Josep, Powderly, John D., Hamid, Omid, Gordon, Michael S., Fisher, George A., Braiteh, Fadi S., Garbo, Lawrence E., Fine, Gregg Daniel, Kowanetz, Marcin, McCall, Bruce, Shen, Xiaodong, Chen, Daniel S., Kohrt, Holbrook Edwin

“…Abstract only 3622 Background: PD-L1 has been reported to be expressed broadly in human cancer and can lead to inhibition of anti-tumor T-cell responses…”
Get full text

A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors by Richards, Donald A., Braiteh, Fadi S., Anthony, Stephen Patrick, Edenfield, Jeff, Hellerstedt, Beth A., Raju, Robert N., Conkling, Paul, Smith, David A., Becerra, Carlos, Cohn, Allen Lee, Denlinger, Crystal Shereen, Garbo, Lawrence E., Wu, Hillary H., Garcia, Agustin, McDonagh, Charlotte, Frye, Sasha, Agresta, Samuel V., Moyo, Victor M.

“…Abstract only TPS3111 Background: The HER2/HER3 oncogenic heterodimer is a potent HER receptor pairing with respect to strength of interaction, receptor…”
Get full text

A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors by Becerra, Carlos, Infante, Jeffrey R., Garbo, Lawrence E., Gordon, Michael S., Smith, David A., Braiteh, Fadi S., Gandara, David R., Jotte, Robert M., Reckamp, Karen L., Janku, Filip, Burris, Howard A., Bellew, Kevin M., Gardner, Olivia S., Liu, Li, Cox, Donna S, Peddareddigari, Vijay Gopal Reddy, Blumenschein, George R.

“…Abstract only 3023 Background: Trametinib, an oral MEK1/MEK2 inhibitor, has demonstrated single-agent clinical activity. In vitro studies of trametinib plus…”
Get full text

Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors by Sausville, E. A., Garbo, L. E., Weiss, G. J., Shkolny, D., Yurkovetskiy, A. V., Bethune, C., Ramanathan, R. K., Fram, R. J.

“…Abstract only…”
Get full text

A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) by Kindler, H. L., Richards, D. A., Stephenson, J., Garbo, L. E., Rocha Lima, C. S., Safran, H., Wiezorek, J. S., Feigal, E. G., Bray, S., Fuchs, C.

“…Abstract only…”
Get full text

Results of a Nonrandomized, Open-Label, Phase II Study of Combined Gemcitabine, Mitoxantrone, and Rituximab in Relapsed or Refractory Mantle Cell Lymphoma by Garbo, Lawrence E., Flynn, Patrick J., MacRae, Margaret A., Rauch, Mary A., Wang, Yunfei, Kolibaba, Kathryn S.

“…Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that usually presents as disseminated disease. Prognosis is poor, and…”
Get full text